P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer's Disease. (1st July 2016) - Blaettler, Thomas; Smith, Janice; Smith, Jillian; Paul, Robert; Asnaghi, Veronica; Fuji, Reina; Quartino, Angelica; Honigberg, Lee; Rabbia, Michael A.; Yule, Susan; Ostrowitzki, Susanne; Fontoura, Paulo